197 related articles for article (PubMed ID: 34739914)
1. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
Talbot J; Højsgaard Chow H; Holm Hansen R; von Essen MR; Sellebjerg F
J Neuroimmunol; 2021 Dec; 361():577756. PubMed ID: 34739914
[TBL] [Abstract][Full Text] [Related]
2. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.
Højsgaard Chow H; Talbot J; Lundell H; Gøbel Madsen C; Marstrand L; Lange T; Mahler MR; Buhelt S; Holm Hansen R; Blinkenberg M; Romme Christensen J; Soelberg Sørensen P; Rode von Essen M; Siebner HR; Sellebjerg F
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429340
[TBL] [Abstract][Full Text] [Related]
3. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.
Højsgaard Chow H; Talbot J; Lundell H; Marstrand L; Gøbel Madsen C; Bach Søndergaard H; Bredahl Hansen M; Solberg Sørensen P; Siebner HR; Sellebjerg F
Mult Scler Relat Disord; 2023 Feb; 70():104458. PubMed ID: 36586351
[TBL] [Abstract][Full Text] [Related]
5. Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use.
Paik J
CNS Drugs; 2021 Jun; 35(6):691-700. PubMed ID: 34057708
[TBL] [Abstract][Full Text] [Related]
6. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
7. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
8. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Blair HA
Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
[TBL] [Abstract][Full Text] [Related]
9. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal CD8
von Essen MR; Talbot J; Hansen RHH; Chow HH; Lundell H; Siebner HR; Sellebjerg F
Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37369602
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
12. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
13. B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate.
Høglund RA; Polak J; Vartdal F; Holmøy T; Lossius A
Mult Scler Relat Disord; 2018 Nov; 26():90-95. PubMed ID: 30243235
[TBL] [Abstract][Full Text] [Related]
14. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
Yadav SK; Soin D; Ito K; Dhib-Jalbut S
J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
[TBL] [Abstract][Full Text] [Related]
15. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
[TBL] [Abstract][Full Text] [Related]
16. Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells.
Schlöder J; Berges C; Luessi F; Jonuleit H
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134847
[TBL] [Abstract][Full Text] [Related]
17. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
[TBL] [Abstract][Full Text] [Related]
19. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
20. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
